Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a newly diagnosed RCC, with a primary tumor diameter of more than 4 cm (\>= T1b), not previously treated, and be a candidate for operative tumor resection~* Be willing and able to undergo pre-treatment baseline image-guided core biopsy of their primary RCC~* Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale~* Demonstrate adequate organ function~* Female is not breast feeding, is postmenopausal or surgically sterile; demonstrates non-pregnant state, and agrees to use two acceptable methods of birth control throughout the trial, until 120 days after the last dose of treatment~* Male with female partner of childbearing potential agrees to use adequate method of contraception throughout study, until 120 days after last dose of treatment or last blood draw.~Exclusion Criteria:~* Is currently participating in, or has participated in a study with an investigational agent or device within 4 weeks prior to first dose of study therapy~* Has a diagnosis of immunosuppression or has received systemic steroid therapy, or any other form of immunosuppressive therapy within 4 weeks prior to first dose of study therapy~* Has had prior chemotherapy, targeted small molecule, or radiation therapy for treatment of RCC~* Has a known additional (other than RCC) malignancy that is progressing or requires active treatment~* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis~* Has an active, or documented history of autoimmune disease, with the exceptions of vitiligo or resolved childhood asthma/atopy~* Has a history of (non-infectious) pneumonitis that required treatment with steroids or current pneumonitis.~* Has an active infection requiring systematic therapy~* Is receiving anticoagulant therapy, with the exception of low dosage aspirin~* Has severe cardiovascular disease or symptomatic ischemic heart disease~* Has hepatic decompensation~* Has uncontrolled thyroid dysfunction~* Has uncontrolled diabetes mellitus~* Has known psychiatric or substance abuse disorders~* Female is pregnant or breastfeeding~* Is expecting to conceive children within the projected maximum duration of the trial, extending through 120 days after the last dose of treatment or the last blood draw~* Has received prior therapy with any antibody or drug (including ipilimumab) specifically targeting T-cell co-stimulation or checkpoint pathway~* Has a known history of human immunodeficiency virus (HIV)~* Has known active hepatitis B or C~* Has received a live vaccine within 30 days prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neoadjuvant Pembrolizumab + RCC Resection (Type: EXPERIMENTAL): Participants received pembrolizumab, 200 mg intravenously (IV) once every 3-week cycle for up to 2 cycles followed by standard of care (SOC) renal cell carcinoma (RCC) surgical resection; and then received post-resection pembrolizumab 200 mg IV once every 3 week cycle for up to approximately 1 year (17 cycles). Post-resection pembrolizumab was only administered to participants who enrolled after Protocol Amendment 04.
- RCC Resection (Type: EXPERIMENTAL): Participants received SOC renal cell carcinoma (RCC) surgical resection; and then may have received post-resection pembrolizumab 200 mg IV once every 3 week cycle for up to approximately 1 year (17 cycles). Post-resection pembrolizumab was only administered to participants who enrolled under Protocol Amendment 04.

Based on this trial design, predict the completion outcome and termination type (if applicable).